AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20951282 — intervention group
Group type: COMPARATOR
Intervention: Working length determined by working length radiograph (Group 1)
Number of subjects: 84
Study 17486065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 100
Study 17486065 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 100
Study 16029678 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% green tea cream and 300 mg twice‐daily green tea oral supplementation
Number of subjects: 40
Study 16029678 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 40
Study 11916197 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 54
Study 11916197 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal band ligation (VBL)
Number of subjects: 54
Study 10191238 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfection group (previously infected with 35000HP)
Number of subjects: 14
Study 10191238 — intervention group
Group type: COMPARATOR
Intervention: Control group (naive subjects)
Number of subjects: 14
Study 10191238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 7595849 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of hernial sac/processus vaginalis (total of 236 hernial sacs)
Number of subjects: 798
Study 7595849 — intervention group
Group type: COMPARATOR
Intervention: Distal splitting of hernial sac/processus vaginalis (total of 595 residual hernial sacs)
Number of subjects: 798
Study 2336525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasometry
Number of subjects: 15
Study 2336525 — intervention group
Group type: COMPARATOR
Intervention: Active anterior rhinomanometry
Number of subjects: 15
Study 598301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24 g i.v. Theophylline-ethylenediamine
Number of subjects: 45
Study 598301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.72 g infusion over four hours
Number of subjects: 45
Study 598301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.36 g i.m. injection
Number of subjects: 45
Study 598301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.72 g infusion over 6-8 hours
Number of subjects: 45
Study 28198783 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Training (MCT group)
Number of subjects: 20
Study 28198783 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT group)
Number of subjects: 20
Study 30230204 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term administration of human albumin (20 g twice per week)
Number of subjects: 70
Study 30230204 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SOC)
Number of subjects: 70
Study 27161901 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 595
Study 27161901 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus lifestyle intervention
Number of subjects: 595
Study 27161901 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight changes across treatment arms
Number of subjects: 595
Study 27161901 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change of ≥ 7% in overweight
Number of subjects: 595
Study 27161901 — intervention group
Group type: EXPERIMENTAL
Intervention: Full TODAY sample weight changes
Number of subjects: 595
Study 25962383 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil (SO) lipid emulsion
Number of subjects: 42
Study 25962383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) lipid emulsion
Number of subjects: 42
Study 25962383 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (C)
Number of subjects: 42
Study 23563184 — intervention group
Group type: EXPERIMENTAL
Intervention: Native smartphone application
Number of subjects: 24
Study 23563184 — intervention group
Group type: COMPARATOR
Intervention: SMS text-only implementation
Number of subjects: 24
Study 21617110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime treatment with ≥1 hypertension medications
Number of subjects: 448
Study 21617110 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (all medications ingested in the morning)
Number of subjects: 448
Study 19471029 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated care (intervention group)
Number of subjects: 490
Study 19471029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 490
Study 16501287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with Mt-PA pre-administration (group T)
Number of subjects: 44
Study 16501287 — intervention group
Group type: COMPARATOR
Intervention: Thrombectomy alone (group N)
Number of subjects: 44
Study 14629070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound‐assisted liposuction (UAL)
Number of subjects: 40
Study 14629070 — intervention group
Group type: COMPARATOR
Intervention: Surgical lipectomy
Number of subjects: 40
Study 10792199 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 47
Study 10792199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9487417 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding training for community health workers
Number of subjects: 0
Study 7690046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent dosing system (IDS) for FK506
Number of subjects: 147
Study 2876122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged continuous treatment with propranolol and other anti-arrhythmic drugs
Number of subjects: 329
Study 2876122 — intervention group
Group type: COMPARATOR
Intervention: Control group treated in local outpatient clinics
Number of subjects: 329
Study 30158072 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based treatment
Number of subjects: 8580
Study 30158072 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 8580
Study 30158072 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 8580
Study 30158072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8580
Study 30158072 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-LLA group (no lipid-lowering treatment) with amlodipine
Number of subjects: 8580
Study 30158072 — intervention group
Group type: COMPARATOR
Intervention: Non-LLA group (no lipid-lowering treatment) with atenolol
Number of subjects: 8580
Study 28659038 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint treatment (fluoxetine + CBT)
Number of subjects: 195
Study 28659038 — intervention group
Group type: EXPERIMENTAL
Intervention: Single active treatment (fluoxetine or CBT)
Number of subjects: 195
Study 28659038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 28659038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 195
Study 28659038 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 195
Study 24024528 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading a text about genetic etiology of homosexual sexual orientation
Number of subjects: 190
Study 24024528 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading a text about environmental etiology of homosexual sexual orientation
Number of subjects: 190
Study 24024528 — intervention group
Group type: COMPARATOR
Intervention: Traditional opposition to same-sex parenting
Number of subjects: 190
Study 24093845 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided group
Number of subjects: 350
Study 24093845 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided group
Number of subjects: 350
Study 20199136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime pramlintide (PRAM) 120 microg fixed dose
Number of subjects: 112
Study 20199136 — intervention group
Group type: COMPARATOR
Intervention: Titrated rapid-acting insulin analogs (RAIAs)
Number of subjects: 112
Study 18251641 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + CHX
Number of subjects: 116
Study 18251641 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 116
Study 16627888 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with mildly abnormal general movements (GMs)
Number of subjects: 0
Study 16627888 — intervention group
Group type: COMPARATOR
Intervention: Normal GMs
Number of subjects: 0
Study 12739832 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (150 microg)
Number of subjects: 61
Study 12739832 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (not specified dose)
Number of subjects: 61
Study 12739832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 61
Study 11789263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood (ILIB) therapy
Number of subjects: 75
Study 11789263 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicine (CM)
Number of subjects: 75
Study 9383258 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg/day
Number of subjects: 20
Study 9383258 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg/day
Number of subjects: 20
Study 8222794 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily for 7 to 14 days)
Number of subjects: 213
Study 8222794 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (400 mg once daily for 7 to 14 days)
Number of subjects: 213
Study 3899369 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 18
Study 3899369 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 18
Study 30370463 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging situation
Number of subjects: 110
Study 30370463 — intervention group
Group type: COMPARATOR
Intervention: Control situation
Number of subjects: 110
Study 29309090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 64
Study 26726885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400mg every 8 hrs)
Number of subjects: 15
Study 26726885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24193180 — intervention group
Group type: EXPERIMENTAL
Intervention: Active prewarming with a forced-air warmer connected to a prewarming suit (Group C)
Number of subjects: 90
Study 24193180 — intervention group
Group type: COMPARATOR
Intervention: Passive preoperative insulation with a commercial prewarming suit (Group B)
Number of subjects: 90
Study 24193180 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative insulation (Group A)
Number of subjects: 90
Study 22267495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral drainage approach
Number of subjects: 40
Study 22267495 — intervention group
Group type: COMPARATOR
Intervention: External cervical approach
Number of subjects: 40
Study 20445836 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 47
Study 20445836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 18983789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with midazolam (30 ml of 0.5% bupivacaine with midazolam 50 microg x kg‐1)
Number of subjects: 50
Study 18983789 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (30 ml of 0.5% bupivacaine)
Number of subjects: 50
Study 16088231 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMID regimen (mitoxantrone, VP16, methylglyoxal, ifosfamide and dexamethasone)
Number of subjects: 149
Study 16088231 — intervention group
Group type: COMPARATOR
Intervention: CEOP regimen (cyclophosphamide, epirubicin, vincristine and prednisone)
Number of subjects: 149
Study 12143030 — intervention group
Group type: EXPERIMENTAL
Intervention: Human patient simulator experience before clerkship examination (Group I)
Number of subjects: 90
Study 12143030 — intervention group
Group type: COMPARATOR
Intervention: Self-study before clerkship examination (Group II)
Number of subjects: 90
Study 11074901 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (patient education, training for participation, self-monitoring of prothrombin time, guideline-based management of warfarin dosing)
Number of subjects: 325
Study 11074901 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325
Study 11074901 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 325
Study 9307534 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 48
Study 9307534 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemeprost
Number of subjects: 48
Study 9307534 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 48
Study 9307534 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 48
Study 8315546 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 2 mg/kg (M)
Number of subjects: 71
Study 8315546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose meperidine 1 mg/kg and diazepam 0.1 mg/kg (M low+D)
Number of subjects: 71
Study 8315546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose meperidine 2 mg/kg and diazepam 0.1 mg/kg (M high+D)
Number of subjects: 71
Study 8315546 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.1 mg/kg (D)
Number of subjects: 71
Study 15791756 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental interviewing behaviors
Number of subjects: 0
Study 30368429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic gait analysis
Number of subjects: 25
Study 30368429 — intervention group
Group type: COMPARATOR
Intervention: Stationary gait analysis
Number of subjects: 25
Study 27247843 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (active-comparator)
Number of subjects: 615
Study 27247843 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (placebo-controlled)
Number of subjects: 615
Study 27247843 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (active-comparator)
Number of subjects: 615
Study 27247843 — intervention group
Group type: COMPARATOR
Intervention: Medication (placebo)
Number of subjects: 615
Study 27247843 — intervention group
Group type: COMPARATOR
Intervention: Medication (medication)
Number of subjects: 615
Study 27247843 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy (psychotherapy)
Number of subjects: 615
Study 25591522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sermion (nicergoline)
Number of subjects: 880
Study 22460061 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 101
Study 22460061 — intervention group
Group type: COMPARATOR
Intervention: No preimplantation genetic screening (PGS)
Number of subjects: 101
Study 20497949 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Score (GDS) > or = 6
Number of subjects: 2656
Study 20497949 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional GDS point at baseline
Number of subjects: 2656
Study 18771363 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 24
Study 18771363 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone (control)
Number of subjects: 24
Study 16227473 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus patients
Number of subjects: 36
Study 16227473 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study 16227473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 12566494 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 2 mg Cu/d for 6 weeks
Number of subjects: 17
Study 12566494 — intervention group
Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 17
Study 12566494 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 1.0 mg Cu/d during equilibration
Number of subjects: 17
Study 10385496 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ascorbic acid (2 g PO)
Number of subjects: 46
Study 10385496 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ascorbic acid (500 mg/d)
Number of subjects: 46
Study 10385496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8909308 — intervention group
Group type: EXPERIMENTAL
Intervention: TF + N‐CWS (n = 41)
Number of subjects: 82
Study 8909308 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery only) (n = 41)
Number of subjects: 82
Study 1872141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 397
Study 1872141 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 397
Study 1872141 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment group
Number of subjects: 397
Study 31119466 — intervention group
Group type: EXPERIMENTAL
Intervention: IP6 (600 mg twice daily)
Number of subjects: 31
Study 31119466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 28223407 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in high genetic risk group
Number of subjects: 4910
Study 28223407 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy in all others
Number of subjects: 4910
Study 28223407 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of WOSCOPS, ASCOT, and JUPITER
Number of subjects: 4910
Study 28223407 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score increase
Number of subjects: 4910
Study 25879821 — intervention group
Group type: EXPERIMENTAL
Intervention: acute moderate physical activity for 30 min
Number of subjects: 50
Study 25879821 — intervention group
Group type: COMPARATOR
Intervention: sedentary activity for 30 min
Number of subjects: 50
Study 25879821 — intervention group
Group type: EXPERIMENTAL
Intervention: acute moderate physical activity
Number of subjects: 50
Study 25879821 — intervention group
Group type: EXPERIMENTAL
Intervention: positive parenting
Number of subjects: 50
Study 23348636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 500 mg BID for 12 weeks + Peg-IFNα-2a/RBV
Number of subjects: 0
Study 23348636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 1000 mg BID for 8 weeks + Peg-IFNα-2a/RBV
Number of subjects: 0
Study 23348636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 1000 mg BID for 12 weeks + Peg-IFNα-2a/RBV
Number of subjects: 0
Study 23348636 — intervention group
Group type: COMPARATOR
Intervention: Placebo BID for 12 weeks + Peg-IFNα-2a/RBV
Number of subjects: 0
Study 21331518 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 19
Study 21331518 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 19
Study 19297102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17‐beta estradiol daily and 0.35 mg norethindrone 3 days/week
Number of subjects: 142
Study 19297102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 17989859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (50 g daily for 3 months)
Number of subjects: 74
Study 17989859 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 74
Study 15381516 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy (up to 6 treatment sessions in a 12-week period)
Number of subjects: 150
Study 15381516 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 150
Study 15381516 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy
Number of subjects: 150
Study 11378603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (loading bolus of 300 mg followed by a continuous infusion of 1.5 mg.kg‐1.hr‐1 until the second postoperative day)
Number of subjects: 40
Study 11378603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 40
Study 11378603 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 40
Study 9643403 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal Resistance Index (RI)
Number of subjects: 78
Study 9643403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral diastolic notch
Number of subjects: 78
Study 9643403 — intervention group
Group type: COMPARATOR
Intervention: Unilateral notch
Number of subjects: 78
Study 8078656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with vasopressin 25 IU% and noradrenaline bitartrate
Number of subjects: 0
Study 8078656 — intervention group
Group type: COMPARATOR
Intervention: Other three lidocaine solutions (not specified)
Number of subjects: 0
Study 2676654 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day lovastatin
Number of subjects: 32
Study 2676654 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/day clofibrate
Number of subjects: 32
Study 2676654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 775086 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 61
Study 775086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 31759901 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs in advance care planning (ACP)
Number of subjects: 140
Study 31759901 — intervention group
Group type: COMPARATOR
Intervention: Usual care by control group GPs
Number of subjects: 140
Study 30577971 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTIPLE (8 trip-like gait perturbations)
Number of subjects: 24
Study 30577971 — intervention group
Group type: COMPARATOR
Intervention: SINGLE (1 trip-like gait perturbation)
Number of subjects: 24
Study 26561424 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 26561424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5%, 2%, and 5%)
Number of subjects: 20
Study 26561424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (decreasing concentration order)
Number of subjects: 20
Study 26561424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (increasing concentration order)
Number of subjects: 20
Study 25973909 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-089 (5, 10, 15, 20, 30, or 35 mg once daily)
Number of subjects: 337
Study 25973909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337